Predictors of 12-week remission in a nationwide cohort of people with depressive disorders

The CRESCEND study

Jae Min Kim, Sung Wan Kim, Robert Stewart, Seon Young Kim, Jin Sang Yoon, Sung Won Jung, Min-Soo Lee, Hyeon Woo Yim, Tae Youn Jun

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objective: To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods: For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier. Results: For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome.

Original languageEnglish
Pages (from-to)41-50
Number of pages10
JournalHuman Psychopharmacology
Volume26
Issue number1
DOIs
Publication statusPublished - 2011 Jan 1

Fingerprint

Depressive Disorder
Suicide
Anxiety
Citalopram
Republic of Korea
Diagnostic and Statistical Manual of Mental Disorders
Health Status
Depression
Therapeutics

Keywords

  • Anxiety
  • Depression
  • Korea
  • Parasuicide
  • Remission

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Kim, J. M., Kim, S. W., Stewart, R., Kim, S. Y., Yoon, J. S., Jung, S. W., ... Jun, T. Y. (2011). Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: The CRESCEND study. Human Psychopharmacology, 26(1), 41-50. https://doi.org/10.1002/hup.1168

Predictors of 12-week remission in a nationwide cohort of people with depressive disorders : The CRESCEND study. / Kim, Jae Min; Kim, Sung Wan; Stewart, Robert; Kim, Seon Young; Yoon, Jin Sang; Jung, Sung Won; Lee, Min-Soo; Yim, Hyeon Woo; Jun, Tae Youn.

In: Human Psychopharmacology, Vol. 26, No. 1, 01.01.2011, p. 41-50.

Research output: Contribution to journalArticle

Kim, JM, Kim, SW, Stewart, R, Kim, SY, Yoon, JS, Jung, SW, Lee, M-S, Yim, HW & Jun, TY 2011, 'Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: The CRESCEND study', Human Psychopharmacology, vol. 26, no. 1, pp. 41-50. https://doi.org/10.1002/hup.1168
Kim, Jae Min ; Kim, Sung Wan ; Stewart, Robert ; Kim, Seon Young ; Yoon, Jin Sang ; Jung, Sung Won ; Lee, Min-Soo ; Yim, Hyeon Woo ; Jun, Tae Youn. / Predictors of 12-week remission in a nationwide cohort of people with depressive disorders : The CRESCEND study. In: Human Psychopharmacology. 2011 ; Vol. 26, No. 1. pp. 41-50.
@article{748e735e3a2a43a3bf4b2daf6bc7159e,
title = "Predictors of 12-week remission in a nationwide cohort of people with depressive disorders: The CRESCEND study",
abstract = "Objective: To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods: For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier. Results: For 723 participants, the 12-week remission rate was 31.4{\%}. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome.",
keywords = "Anxiety, Depression, Korea, Parasuicide, Remission",
author = "Kim, {Jae Min} and Kim, {Sung Wan} and Robert Stewart and Kim, {Seon Young} and Yoon, {Jin Sang} and Jung, {Sung Won} and Min-Soo Lee and Yim, {Hyeon Woo} and Jun, {Tae Youn}",
year = "2011",
month = "1",
day = "1",
doi = "10.1002/hup.1168",
language = "English",
volume = "26",
pages = "41--50",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - Predictors of 12-week remission in a nationwide cohort of people with depressive disorders

T2 - The CRESCEND study

AU - Kim, Jae Min

AU - Kim, Sung Wan

AU - Stewart, Robert

AU - Kim, Seon Young

AU - Yoon, Jin Sang

AU - Jung, Sung Won

AU - Lee, Min-Soo

AU - Yim, Hyeon Woo

AU - Jun, Tae Youn

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Objective: To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods: For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier. Results: For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome.

AB - Objective: To estimate the 12-week remission rate of patients with depressive disorders and predictors of this in a naturalistic clinical setting in South Korea. Methods: For people with DSM-IV depressive disorders about to receive treatment at 18 hospitals, data on sociodemographic and health status were obtained. A free choice of clinical interventions was allowed and naturalistic follow-up took place at 1, 2, 4, 8, and 12 weeks later. Remission was defined as a Hamilton Depression Rating Scale score of ≤7 sustained to 12 weeks or last follow-up, if earlier. Results: For 723 participants, the 12-week remission rate was 31.4%. Remission was more likely in women, and in patients without a prior history of suicide attempt, and those with lower baseline anxiety. Conclusions: Remission associated with unrestricted clinical interventions was comparable to STAR*D estimates for citalopram alone. Comorbid anxiety and previous suicide attempt were markers of worse outcome.

KW - Anxiety

KW - Depression

KW - Korea

KW - Parasuicide

KW - Remission

UR - http://www.scopus.com/inward/record.url?scp=79953238716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953238716&partnerID=8YFLogxK

U2 - 10.1002/hup.1168

DO - 10.1002/hup.1168

M3 - Article

VL - 26

SP - 41

EP - 50

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 1

ER -